Short-term Effects of Intravitreal Bevacizumab and Triamcinolone in Patients With Diabetic Macular Edema

NCT ID: NCT00563940

Last Updated: 2019-07-08

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 30 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2007-03-31
• Study Completion Date: 2010-02-28

Brief Summary

Diabetic macular edema is a common complication of ocular diabetes mellitus and can cause blindness. Hypoxygenation of the retina stimulates tissue mediators, especially different subtypes of vascular endothelial growth factor (VEGF). VEGF is responsible for proliferation, extension and increased permeability of the vessels. The aim of our study was to examine the short-term effect of intravitreal bevacizumab (Avastin® 1.25 mg in 0.05 ml) and triamcinolone on visual acuity and central retinal thickness in patients with clinically significant diabetic macular edema (CSME).

Conditions

Diabetic Macular Edema

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: PROSPECTIVE

Study Groups

1

No interventions assigned to this group

2

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• clinical significant macular edema

Exclusion Criteria

• retinal thickness < 250 µm

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Bern

OTHER

Sponsor Role: collaborator

Insel Gruppe AG, University Hospital Bern

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ute Wolf-Schnurrbusch, MD

Role: PRINCIPAL_INVESTIGATOR

University of Bern

Sebastian Wolf, MD PhD

Role: STUDY_DIRECTOR

University of Bern

Locations

Klinik und Poliklinik für Augenheilkunde

Bern, , Switzerland

Countries

Switzerland

Other Identifiers

KEK E: 29-03-07

Identifier Type: -

Identifier Source: secondary_id

AUG 044/07

Identifier Type: -

Identifier Source: org_study_id